No germline FH mutations in familial breast cancer patients

Maija Helena Tuulia Kiuru, Rainer Lehtonen, Hannaleena Eerola, Kristiina Aittomäki, Carl Blomqvist, Heli Nevanlinna, Lauri A Aaltonen, Virpi Launonen

Research output: Contribution to journalArticleScientificpeer-review

Abstract

Fumarate hydratase (FH) was recently identified as the predisposing gene for a tumor predisposition syndrome, hereditary leiomyomatosis and renal cell cancer (HLRCC) (MIM 605839). In HLRCC, individuals with a germline heterozygous mutation in the FH gene typically develop benign leiomyomas of the skin and the uterus ( fibroids, myomas). In a subset of the families, predisposition to renal cell carcinoma and uterine leiomyosarcoma occurs. Other malignancies including breast cancer have also been detected in patients with a germline FH mutation. To examine whether FH could be involved in predisposition to breast cancer, we analyzed germline FH mutations from 85 Finnish breast cancer patients. Most of the cases were selected based on positive family or personal history for malignancies associated with HLRCC. No mutations were found. These results show that FH is not a major predisposing gene for familial breast cancer.
Original languageEnglish
JournalEuropean Journal of Human Genetics
Volume13
Issue number4
Pages (from-to)506-509
Number of pages4
ISSN1018-4813
DOIs
Publication statusPublished - 2005
MoE publication typeA1 Journal article-refereed

Fields of Science

  • breast cancer
  • FH
  • fumarase
  • fumarate hydratase
  • leiomyomas
  • renal cancer
  • sarcoma
  • RENAL-CELL CANCER
  • FUMARATE HYDRATASE MUTATIONS
  • HEREDITARY LEIOMYOMATOSIS
  • UTERINE LEIOMYOMATA
  • BRCA2 MUTATIONS
  • PROSTATE-CANCER
  • GENE
  • SUSCEPTIBILITY
  • LINKAGE
  • PREDISPOSE
  • 312 Clinical medicine
  • Obstetrics and gynecology

Cite this